Image
Personalized care starts here.
With over 450 oncology tests — including biomarker testing, hereditary cancer risk assessments, next-generation sequencing (NGS), and molecular disease detection — we provide the answers you need to help guide decisions with confidence.
Meet with our team to explore how we can help you navigate complex diagnostic needs and improve patient outcomes.
View our posters
Session Date & Time | Details | Title | Presenter |
Saturday, May 31, 2025 | |||
| Saturday, May 31 9:00 AM - 12:00 PM CDT | Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster #: 444 | Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma | Heidi C. Ko, DO |
| Saturday, May 31 9:00 AM - 12:00 PM CDT | Session: Gastrointestinal Cancer—Colorectal and Anal Poster #: 273 | Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy. | Ingrid Franken, MD, MSc University Medical Center Utrecht |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Lung Cancer—Non-Small Cell Metastatic Poster #: 138a | A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). | Valsamo Anagnostou, MD, PhD Johns Hopkins School of Medicine |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Prevention, Risk Reduction, and Genetics Poster #: 315 | Clinical utility of germline genetic testing in diverse cancer types. | Judy Ellen Garber, MD, FASCO, MPH Dana-Farber Cancer Institute |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Prevention, Risk Reduction, and Genetics Poster #: 295 | Preventative intervention uptake among women with breast cancer and pathogenic germline variants. | Sarah Nielsen Young, CGC, MS |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Prevention, Risk Reduction, and Genetics Poster #: 294 | Implementation of Pan-Cancer Universal Germline Testing in an Ethnically Diverse and Rural Community Oncology Practice. | Sarah Nielsen Young, CGC, MS |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Prevention, Risk Reduction, and Genetics Poster #: 296 | Better together: synergy of germline and somatic testing in HRR pathway-driven cancers. | Michelle F. Green, PhD |
| Saturday, May 31 1:30 - 4:30 PM CDT | Session: Quality Care/Health Services Research Poster #: 419 | Insurance coverage of germline genetic testing for ovarian, pancreatic, and early-onset colorectal, endometrial, and breast cancers, stratified by self-reported race and ethnicity. | Erica M. Vaccari, BS, MS |
Sunday, June 1, 2025 | |||
| Sunday, June 1 11:15 AM - 12:45 PM CDT | Session: Developmental Therapeutics—Immunotherapy Oral Presentation | Natural Killer Cell Transcriptomic Expression Predicts Better Survival after Immune Checkpoint Blockade across Cancers | Hirotaka Miyashita, MD Dartmouth Cancer Center |
Monday, June 2, 2025 | |||
| Monday, June 2 9:00 AM - 12:00 PM CDT | Session: Genitourinary Cancer—Prostate, Testicular, and Penile Poster #: 248 | Uptake of targeted therapy in a large cohort of patients with advanced prostate cancer and germline pathogenic variant. | Hiba M. Khan, MD, MPH University of Washington/Fred Hutch Cancer Center |
| Monday, June 2 9:00 AM - 12:00 PM CDT | Session: Breast Cancer - Metastatic Poster #: 5 | Decoding HER2 Dynamics: Exploring HER2 expression across a real-world breast cancer cohort. | Michelle F. Green, PhD |
| Monday, June 2 1:30 - 4:30 PM CDT | Session: Developmental Therapeutics—Immunotherapy Poster #: 272 | Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators predict longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers. | Yu Fujiwara, MD |
| Monday, June 2 1:30 - 4:30 PM CDT | Session: Developmental Therapeutics—Immunotherapy Poster #: 284 | The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts). | Obada Ehab Ababneh, MD Unniv Texas MD Anderson Cancer Center |
| Monday, June 2 1:30 - 4:30 PM CDT | Session: Developmental Therapeutics—Immunotherapy Poster #: 197 | Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer. | Blair Landon Sidney Kimmel, Johns Hopkins School of Medicine |
| Monday, June 2 1:30 - 4:30 PM CDT | Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster #: 367 | Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA genomic profiling in patients with advanced or metastatic solid tumors. | Amna Jamali, MBBS, Johns Hopkins School of Medcine |
| Monday, June 2 1:30 - 4:30 PM CDT | Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster #: 449 | Combined prognostic value of post-surgery circulating tumor DNA and tumor-stroma ratio in patients with stage III colon cancer treated with adjuvant chemotherapy. | Ingrid Franken, MD, MSc University Medical Center Utrecht |